Patents by Inventor Scott Grindrod

Scott Grindrod has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PERSONALIZED METHODS FOR TREATING DISEASE BY RADIOSENSITIZATION
    Publication number: 20170266284
    Abstract: Methods are provided for treating cancer and neoplastic diseases where such methods include the administration of radiosensitizing agents.
    Type: Application
    Filed: September 18, 2015
    Publication date: September 21, 2017
    Inventors: Scott GRINDROD, Anatoly DRITSCHILO, Timothy J KINSELLA
  • DUAL FUNCTION MOLECULES FOR HISTONE DEACETYLASE INHIBITION AND ATAXIA TELANGIECTASIA MUTATED ACTIVATION AND METHODS OF USE THEREOF
    Publication number: 20160257649
    Abstract: Dual function compounds are provided that may be inhibitors of histone deacetylase (HDAC) and activators of ataxia telangiectasia mutated (ATM). Pharmaceutical compositions and methods of use are also provided that utilize such compounds.
    Type: Application
    Filed: March 3, 2015
    Publication date: September 8, 2016
    Inventors: Scott Grindrod, Mira Jung, Milton Brown, Anatoly Dritschilo
  • Na channels, disease, and related assays and compositions
    Patent number: 8816095
    Abstract: Disclosed are molecules and their synthesis, for use in blocking gated ion channels such as voltage-gated sodium channels (VGSCs) and prostate voltage sodium channels (PVSCs). These inhibitors have superior blocking efficacy, for instance in displacing the radioligand [3H]-Batrachotoxin-B ([3H]-BTX-B) that binds to site 2 of a VGSC. The molecules of the invention comprise a moiety which increases the binding affinity of molecules for the protein binding site in prostate cancer cells (PCs), and which is also fluorescent. In one embodiment the invention molecules are an inhibition system that can be used to target over-abundant or hyperactive VGSCs selectively in pain, epilepsy or prostate cancer, inhibiting the proliferation of PCs. The fluorescent moiety also facilitates screening, tracking, and pharmacodynamic studies of the drug in a biological system both in vitro and in vivo.
    Type: Grant
    Filed: August 17, 2009
    Date of Patent: August 26, 2014
    Assignee: Georgetown University
    Inventors: Milton L. Brown, Scott Grindrod, Thomas H. Walls, Todd Hansen, Simeng Suy, Mikell A. Paige
  • NA CHANNELS, DISEASE, AND RELATED ASSAYS AND COMPOSITIONS
    Publication number: 20110230442
    Abstract: Disclosed are molecules and their synthesis, for use in blocking gated ion channels such as voltage-gated sodium channels (VGSCs) and prostate voltage sodium channels (PVSCs). These inhibitors have superior blocking efficacy, for instance in displacing the radioligand [3H]-Batrachotoxin-B ([3H]-BTX-B) that binds to site 2 of a VGSC. The molecules of the invention comprise a moiety which increases the binding affinity of molecules for the protein binding site in prostate cancer cells (PCs), and which is also fluorescent. In one embodiment the invention molecules are an inhibition system that can be used to target over-abundant or hyperactive VGSCs selectively in pain, epilepsy or prostate cancer, inhibiting the proliferation of PCs. The fluorescent moiety also facilitates screening, tracking, and pharmacodynamic studies of the drug in a biological system both in vitro and in vivo.
    Type: Application
    Filed: August 17, 2009
    Publication date: September 22, 2011
    Applicant: GEORGETOWN UNIVERSITY
    Inventors: Milton L. Brown, Scott Grindrod, Thomas H. Walls, Todd Hansen, Simeng Suy, Mikell A. Paige